Recombinant human granulocyte-macrophage colony-stimulating factor as treatment for chronic leg ulcers.
OBJECTIVE
To evaluate the safety and effectiveness of a single subcutaneous perilesional administration of 300 micrograms of recombinant human granulocyte-macrophage colony stimulating factor (rHGM-CSF) for the treatment of chronic leg ulcers.


METHODS
Prospective, descriptive evaluation in an outpatient group.


METHODS
The Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico City.


METHODS
10 patients with chronic leg ulcers.


METHODS
Ulcer diameter and side effects.


RESULTS
After 4 weeks observation, 8 of the 10 ulcers had healed; the other two had a mean diameter decrease of 21%. The only side effect was found in a 58 year old female who complained of moderate perilesional pain two days after having received treatment: it was successfully treated with paracetamol.


CONCLUSIONS
We believe that a single perilesional subcutaneous administration of rhGM-CSF is safe and effective for the treatment of chronic leg ulcers.
Borbolla-Escoboza
J R
JR
Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, México DF. jrborbolla@infosel.net.mx
María-Aceves
R
R
López-Hernández
M A
MA
Collados-Larumbe
M T
MT
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D014647:Varicose Ulcer / Q000188:drug therapy*
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor